pediatric ADHD
The company also announced its intentions to seek FDA approval for EndeavorOTC, its over-the-counter product for adults with ADHD.
The digital therapeutic for children's ADHD symptoms received a De Novo clearance last summer.
The large, multi-site investigation described clear improvement in objective symptoms of pediatric attention deficit, but was a bit muddier when describing subjective measures and long-term efficacy.
Topline data released today by the digital therapeutics company also suggest that its FDA approval-pending treatment continued to deliver benefits with continued use.